fbpx

Billion-Dollar Molecules: Etavopivat, an Allosteric PKR Kinase Activator for Sickle Cell Disease

Billion-Dollar Molecules: Etavopivat, an Allosteric PKR Kinase Activator for Sickle Cell Disease

Abstract. Novo Nordisk has acquired Forma Therapeutics for $1.1B for its primary investigational drug, etavopivat. Etavopivat, a past Molecule of the Month, is an oral, once-daily allosteric activator of pyruvate kinase-R (PKR), which is currently being tested in Phase II/III clinical trials for the treatment of sickle cell disease and other hemoglobinopathies. In this article, we cover:

  • the mechanism of action of the drug
  • the clinical context of the acquired portfolio
  • the details of the deal

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.



already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

Newsletter

Join Subscribers from

…and hundreds more!